Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to determine the optimal dose of orally (tablet)
administered thioctic acid in the treatment of symptoms of diabetic polyneuropathy (dPNP). It
is expected that at least one of the three dosages to be tested (600, 1200, or 1800 mg
tablets) of orally administered thioctic acid improves the symptoms of dPNP as compared to
placebo.
Secondary objectives are evaluations of other variables pertinent to dPNP, safety, and
tolerability.